Table 2.

Univariate and multivariate analysis of overall survival.

Subgroup	Patients (n)	Events (n)	mOS (months)	Hazard ratio (95% CI)	PLog rank	Pcox regression
Any initial PSA decline
Yes	61	28	15.3	0.4 (0.2-0.8)	0.01	n.s.
No	26	11	8.4	1 (reference)
Initial PSA decline ≥50%
Yes	28	10	15.5	0.4 (0.2-0.9)
No	59	29	9.2	1 (reference)	0.03	n.s.
Initial PSA decline ≥30%
Yes	43	18	15.3	0.4 (0.2-0.9)	0.03	n.s.
no	44	21	8.4	1 (reference)
baseline Alkaline phosphatase
<220 U/L	67	32	9.8	0.3 (0.6-1.7)	n.s.	n.s.
>220 U/L	42	22	9.2	1 (reference)
baseline LDH
<240 U/L	33	17	9.8	0.9 (0.6-1.7)	n.s.	n.s.
≥240 U/L	76	37	9.2	1 (reference)
Visceral metastasis
Yes	49	32	6.9	2.0 (1.2-3.6)	0.029	0.006
No	59	21	15.3	1 (reference)
Second line chemotherapy (Cabazitaxel)
Yes	28	18	6.8	2.1 (1.2-3.8)
No	81	36	11.5	1 (reference)	0.005	n.s.
Any best PSA decline
Yes	65	29	15.3	0.4 (0.2-0.8)	0.03	n.s.
No	23	12	8.4	1 (reference)
Best PSA decline ≥50%
Yes	41	16	15.3	0.4 (0.2-0.8)
No	47	25	7.5	1 (reference)	0.008	n.s.
Best PSA decline ≥30%
Yes	51	22	15.3	0.4 (0.2-0.9)	0.01	n.s.
no	37	19	7.5	1 (reference)

PSA = Prostate-specific antigen; LDH = Lactate Dehydrogenase, p-values that remained significant after multivariate analysis are shown in bold.